In short
This article explores the ongoing clinical trials investigating the long-term safety and effectiveness of GTX-102, a treatment for Angelman Syndrome. The trials involve the use of a solution containing various substances, including glucose, anhydrous, which is administered intrathecally. We'll discuss the key aspects of these trials, their objectives, and what they mean for patients with Angelman Syndrome.
At a glance
- Trial Name
- A Long-Term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome
- Main Objective
- Evaluate the long-term safety profile of GTX-102 in subjects with Angelman Syndrome
- Secondary Objective
- Evaluate long-term efficacy in cognitive function, communication, and motor skills
- Treatment
- GTX-102 administered via intrathecal lumbar puncture
- Key Substance
- Glucose, Anhydrous (part of ELLIOTTS B SOLUTION)
- Primary Endpoint
- Treatment-emergent AEs and SAEs, frequency, severity, and relationship to investigational product
- Secondary Endpoints
- Changes in Bayley-4 scores for cognition, communication, and motor skills
- Study Duration
- Until GTX-102 is approved or available in the patient's region
What is GLUCOSE, ANHYDROUS?
GLUCOSE, ANHYDROUS is one of the active substances in a medication called ELLIOTTS B SOLUTION. This solution is designed for intrathecal use, which means it is injected directly into the fluid surrounding the brain and spinal cord. Intrathecal administration is a method used to deliver medications directly to the central nervous system.
ELLIOTTS B SOLUTION is described as a sterile, nonpyrogenic (doesn't cause fever), isotonic solution. It contains several other components besides glucose, including calcium chloride, sodium hydrogen carbonate, potassium chloride, sodium chloride, sodium phosphate, and magnesium sulfate.
Angelman Syndrome: An Overview
Angelman Syndrome (AS) is a rare genetic disorder that primarily affects the nervous system. It is characterized by developmental delays, intellectual disability, severe speech impairment, and problems with movement and balance. People with Angelman Syndrome often have a happy, excitable demeanor with frequent smiling and laughter.
Clinical Trial: Long-Term Safety and Efficacy Study
A clinical trial is being conducted to investigate a treatment called GTX-102 for patients with Angelman Syndrome. This is a Phase III long-term extension (LTE) study for an unapproved product. The study aims to evaluate the long-term safety and effectiveness of GTX-102 in patients who have previously participated in a GTX-102 clinical trial.
Treatment Details
In this study, patients will receive GTX-102 through an intrathecal lumbar puncture. This means the medication is injected directly into the fluid surrounding the spinal cord in the lower back area. The treatment period may continue until GTX-102 is approved and/or becomes available in the patient's geographical region.
Eligibility Criteria
To participate in this study, patients must meet certain criteria:
- Have previously participated in a clinical trial with GTX-102
- Have completed the Loading phase/period of the previous study
- Have approval from the Ultragenyx Medical Monitor
- Be screened within 6 months of the last visit in the prior GTX-102 study
- For females of childbearing potential who are sexually active, use highly effective contraception or abstinence
- For males, agree to remain abstinent or use acceptable contraceptive methods during the study and for at least 3 months after the final dose
Patients may be excluded from the study if they:
- Discontinued the prior GTX-102 study due to treatment-related adverse events
- Have any medical, neurological, or psychological condition that could put them at risk or interfere with study assessments
- Have known hypersensitivity to GTX-102 or its components
- Are pregnant, breastfeeding, or planning to become pregnant during the study
Study Objectives and Endpoints
The main objective of this study is to evaluate the long-term safety profile of GTX-102 in subjects with Angelman Syndrome. Secondary objectives include assessing the long-term efficacy of GTX-102 in improving cognitive function, communication, and motor skills.
The study will measure:
- Treatment-emergent adverse events (AEs) and serious adverse events (SAEs)
- Changes in cognitive abilities, receptive and expressive communication, and gross and fine motor skills using the Bayley-4 assessment tool
Safety Considerations
Patient safety is a primary concern in this study. The following measures are in place:
- Regular monitoring of adverse events throughout the study
- A safety follow-up call 30 days after the end of study visit for patients with new or ongoing treatment-emergent adverse events
- Strict inclusion and exclusion criteria to ensure patient safety
- Continuous assessment of the risk-benefit ratio for each participant
It's important to note that while GLUCOSE, ANHYDROUS is a component of ELLIOTTS B SOLUTION, which is used in this study, the primary focus of the trial is on the investigational product GTX-102. The exact role of GLUCOSE, ANHYDROUS in the treatment of Angelman Syndrome is not specified in the provided information.